New drug tested for Tough-to-Treat ovarian cancer
NCT ID NCT06173037
Summary
This study tested an experimental drug called RC88 in women whose ovarian, fallopian tube, or primary peritoneal cancer had returned and was no longer responding to standard platinum-based chemotherapy. The main goals were to see if the drug could shrink tumors, how long the benefit lasted, and what side effects occurred. It involved 43 participants who had already tried at least three prior lines of therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Provincial Hospital
Hefei, Anhui, 230001, China
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400030, China
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081, China
-
Hubei Cancer Hospital
Wuhan, Hubei, 430079, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410031, China
-
Jilin Cancer Hospital
Changchun, Jilin, 130012, China
-
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, 210008, China
-
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, 200011, China
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
-
Qilu Hospital of Shandong University
Jinan, Shangdong, 250012, China
-
Qingdao Central Hospital
Qingdao, Shandong, 266042, China
-
Second hospital of Shanxi Medical University
Taiyuan, Shanxi, 030001, China
-
Shandong Cancer Hospital, Shandong Cancer Institute
Jinan, Shandong, 250117, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
-
The First Hospital of Jilin University
Changchun, Jilin, 130031, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
-
The West China Second University Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300060, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430023, China
-
Xiangyang Central Hospital
Xiangyang, Hubei, 441021, China
-
Xingtai People's Hospital
Xingtai, Hebei, 054031, China
-
Yunnan Cancer Hospital
Kunming, Yunnan, 650118, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
-
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, 310014, China
-
Zhongda Hospital Southeast University
Nanjing, Jiangsu, 210009, China
-
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, 430071, China
Conditions
Explore the condition pages connected to this study.